
|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
Phase III Trial of Enzastaurin for NHL Patients Initiated
Phase III Trial of Enzastaurin for NHL Patients Initiated
Advertisement
INDIANAPOLISEli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.
Articles in this issue
over 19 years ago
High-Quality Screening Colonoscopy Priority for GI Docsover 19 years ago
Genentech Seeks Expanded Use of Avastin in Breast Cancerover 19 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsover 19 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)over 19 years ago
FDA Approves Revlimid for Myeloma Rxover 19 years ago
Real-Time RT Planning, Delivery in the Bronxover 19 years ago
Racial Disparities in Prostate Ca Recurrenceover 19 years ago
HNPCC Pts May Reject Prophylactic Subtotal ColectomyNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
5



































